Positron Corporation and Boston Scientific Present Promising Growth Strategies
16 Novembro 2011 - 11:16AM
Marketwired
With profit margins for medical equipment and supply manufacturers
already being squeezed via sweeping healthcare reform, companies in
the sector could face more headwinds in the future as industry
experts have begun questioning the FDAs approval process. The
Paragon Report examines investing opportunities in the Medical
Equipment & Supplies industry and provides equity research on
Positron Corporation (OTCBB: POSC) and Boston Scientific
Corporation (NYSE: BSX). Access to the full company reports can be
found at:
www.paragonreport.com/POSC www.paragonreport.com/BSX
Over the summer, The Institute of Medicine recommended that the
US government create a new system of approving medical devices
because the current system does not guarantee the products are
safe. The panel from the Institute for Medicines also said the FDA
should abandon a process that allows for medical devices to be
approved if the manufacturers prove they are similar to devices
that are already on the market. Currently, the FDA approves medical
devices without human studies if it is "substantially equivalent"
to other devices that were previously cleared or that were on the
market before 1975.
The Paragon Report provides investors with an excellent first
step in their due diligence by providing daily trading ideas, and
consolidating the public information available on them. For more
investment research on the Medical Equipment & Supplies
industry register with us free at www.paragonreport.com and get
exclusive access to our numerous stock reports and industry
newsletters.
The FDA says it disagrees with the recommendations and wants to
amend its current process, not overhaul it. The current oversight
system has been simultaneously faulted for inadequate assurance of
safety and efficacy and for suppressing innovation. Since
regulatory approval is dependent on claims of similarity to
previously approved devices, the process can encourage the
development of devices that provide only small improvements at
higher cost than their predecessors.
Positron Corporation operates as a molecular imaging company
providing nuclear medicine technologies and services that are used
in the field of nuclear cardiology. Last week Positron and
Manhattan Isotope Technology LLC. (MIT LLC) entered into a binding
Letter of Intent to acquire MIT LLC. Manhattan Isotope is the
leading commercial resource in the United States with practical
knowledge and experience in all stages of strontium-82
production.
Boston Scientific Corporation develops, manufactures, and
markets medical devices used in various interventional medical
specialties worldwide. It offers implantable devices that monitor
the heart and deliver electricity to treat cardiac abnormalities;
and implantable pacemaker systems used to manage slow or irregular
heart rhythms. Last week the company announced positive outcomes
from its COBRA clinical trial, which evaluated post-dilation of
nitinol stents using CryoPlasty Therapy with the PolarCath
Peripheral Dilatation System compared to stenting with conventional
balloon angioplasty in patients with diabetes presenting with
blockages of the superficial femoral artery (SFA).
The Paragon Report has not been compensated by any of the
above-mentioned publicly traded companies. Paragon Report is
compensated by other third party organizations for advertising
services. We act as an independent research portal and are aware
that all investment entails inherent risks. Please view the full
disclaimer at http://www.paragonreport.com/disclaimer
Add to Digg Bookmark with del.icio.us Add to Newsvine
Positron (PK) (USOTC:POSC)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Positron (PK) (USOTC:POSC)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024
Notícias em tempo-real sobre Positron Corporation (PK) da OTCMarkets bolsa de valores: 0 artigos recentes
Mais Notícias de Paragon Financial Limited